A randomised, double-blind, placebo-controlled trial to determine the effect of the rate of intraduodenal glucose delivery on the glucose-lowering efficacy of vildagliptin in patients with type 2 diabetes

Trial Profile

A randomised, double-blind, placebo-controlled trial to determine the effect of the rate of intraduodenal glucose delivery on the glucose-lowering efficacy of vildagliptin in patients with type 2 diabetes

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Sep 2016 Results presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes
    • 03 Apr 2014 Status changed from not yet recruiting to recruiting as reported by Australian New Zealand Clinical Trials Registry record.
    • 29 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top